Allergen immunotherapy in asthma
Allergology International · 2024
DOI: 10.1016/j.alit.2024.05.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergology International, 2024. Verfasst von Kazuyuki Nakagome und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Allergy Center, Saitama Medical University, Saitama, Japan. Electronic address: nakagomek-tky@umin.ac.jp. Hauptthemen laut MEDLINE: Asthma, Desensitization, Immunologic, Allergens. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Saitama Medical University, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Allergen immunotherapy (AIT), including SCIT and SLIT, is a treatment that involves the administration of allergens to which patients with allergic diseases have been sensitized. HDM-SCIT for asthma is indicated in cases of HDM-sensitized allergic asthma with normal lung function. HDM-SCIT improves asthma symptoms and AHR, and decreases the medication dose. Importantly, AIT can improve other allergic diseases complicated by asthma, such as allergic rhinitis, which can also contribute to the improvement of asthma symptoms. Several studies have suggested that HDM-SLIT also attenuates the risk of asthma exacerbations, and improves lung function in asthma cases with allergic rhinitis. Furthermore, AIT can modify the natural course of allergic diseases, including asthma. For example, the effects of AIT are maintained for at least several years after treatment discontinuation. AIT can prevent the onset of asthma when introduced in allergic rhinitis, and can also inhibit or reduce new allergen sensitizations. Recent data have suggested that AIT may suppress non-targeted allergen-induced immune responses in addition to targeted allergen-induced responses, and suppress infections of the lower respiratory tract by enhancing IFN responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Allergy Center, Saitama Medical University, Saitama, Japan. Electronic address: nakagomek-tky@umin.ac.jp.
- Department of Respiratory Medicine and Allergy Center, Saitama Medical University, Saitama, Japan.
Förderung
- Saitama Medical University
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Nakagome, K., & Nagata, M. (2024). Allergen immunotherapy in asthma. Allergology International. https://doi.org/10.1016/j.alit.2024.05.005
Vancouver
Nakagome K, Nagata M. Allergen immunotherapy in asthma. Allergology International. 2024. doi:10.1016/j.alit.2024.05.005
BibTeX
@article{Nakagome2024,
author = {Nakagome, Kazuyuki and Nagata, Makoto},
title = {Allergen immunotherapy in asthma},
journal = {Allergology International},
year = {2024},
doi = {10.1016/j.alit.2024.05.005}
}
EUVIMED